RT Journal Article
SR Electronic
T1 Update on the OMERACT Magnetic Resonance Imaging Task Force: Research and Future Directions
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 383
OP 385
DO 10.3899/jrheum.131085
VO 41
IS 2
A1 Philip G. Conaghan
A1 Fiona M. McQueen
A1 Paul Bird
A1 Charles Peterfy
A1 Espen Haavardsholm
A1 Frédérique Gandjbakhch
A1 Iris Eshed
A1 Ida K. Haugen
A1 Siri Lillegraven
A1 Uffe Møller Døhn
A1 Bo Ejbjerg
A1 Violaine Foltz
A1 Laura Coates
A1 Pernille Bøyesen
A1 Kay-Geert Hermann
A1 Jane Freeston
A1 Marissa Lassere
A1 Philip O’Connor
A1 Paul Emery
A1 Harry Genant
A1 Mikkel Østergaard
YR 2014
UL http://www.jrheum.org/content/41/2/383.abstract
AB Magnetic resonance imaging (MRI) provides an important biomarker across a range of rheumatological diseases. At the Outcome Measures in Rheumatology (OMERACT) 11 meeting, the MRI task force continued its work of developing and improving the use of MRI outcomes for use in clinical trials. The breadth of pathology in the Rheumatoid Arthritis MRI Score has been strengthened with further work on the development of a joint space narrowing score, and a series of exercises presented at OMERACT 11 demonstrated good reliability and construct validity for this assessment. Understanding the importance of residual inflammation after RA treatment remains a major focus of the group’s work. Analyses were presented on defining the level of synovitis (using MRI scores of a single hand) that would predict absence of erosion progression. The development of the OMERACT Hand Osteoarthritis MRI score has continued with substantial work presented on its iterative development, including pathology definition, scaling, and subsequent reliability of the score. Optimizing the role of MRI as a robust biomarker and surrogate outcome remains a priority for this group.